Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call
Vivos Therapeutics, Inc. (VVOS)
Company Research
Source: GlobeNewswire
LITTLETON, Colo., April 15, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS), a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea (“OSA”), announced it plans to release its full year 2025 financial results after market close today, Wednesday, April 15, 2026. The Company will conduct a conference call at 5:00 pm (Eastern Time) to review the results and provide operational updates. Vivos encourages investors and other interested parties to join its conference call today at 5:00 p.m. Eastern time. Management will discuss further details on topics including Vivos’ strategic collaborations and their anticipated effect on near-term revenue growth and cash burn. To access Vivos’ investor conference call, please dial (800) 717-1738 or (646) 307-1865 for international callers. A replay will be available sho
Show less
Read more
Impact Snapshot
Event Time:
VVOS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VVOS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VVOS alerts
High impacting Vivos Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VVOS
News
- Vivos Therapeutics (VVOS) had its price target lowered by Ascendiant Capital Markets from $5.50 to $3.00. They now have a "buy" rating on the stock.MarketBeat
- Vivos Therapeutics (VVOS) had its "sell (e+)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Vivos Therapeutics (VVOS) had its price target lowered by HC Wainwright from $7.00 to $2.50. They now have a "buy" rating on the stock.MarketBeat
- Vivos Therapeutics Inc (VVOS) Q4 2025 Earnings Call Highlights: Revenue Growth Amid Strategic ... [Yahoo! Finance]Yahoo! Finance
- Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call [Yahoo! Finance]Yahoo! Finance
VVOS
Earnings
- 11/19/25 - Beat
VVOS
Analyst Actions
- 4/22/26 - Ascendiant Capital
VVOS
Sec Filings
- 4/22/26 - Form 8-K
- 4/15/26 - Form 8-K
- 4/15/26 - Form 10-K
- VVOS's page on the SEC website